- Genesis to receive an up front and is eligible to receive pre/ clinical and regulatory milestones along with royalties on sales of approved drugs emerges from the collaboration
- The collaboration leverages Genesis’ graph machine learning and drug discovery expertise to identify drug candidates for therapeutic targets across multiple disease areas
- Genesis has developed Dynamic PotentialNet and other neural network algorithms, examining drug-target complexes as flexible, spatial graphs, with the advantage of superior potency and selectivity prediction uniquely toward novel, previously undruggable targets and characterized therapeutic targets
Click here to read full press release/ article | Ref: BusinessWire | Image: BusinessWire
The post Roche Collaborates with Genesis Therapeutics for AI-Driven Drug Discovery first appeared on PharmaShots.